Skip to search formSkip to main contentSkip to account menu

sotatercept

Known as: Decoy Activin Receptor ACE-011 
A soluble fusion protein composed of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc portion of human IgG1 with… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ACE-011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Myelodysplastic syndrome Transforming growth factor ( TGF )-β pathway as a therapeutic target in lower risk myelodysplastic syndromes
The transforming growth factor (TGF)-β superfamily comprises more than 30 soluble growth factors that play a central role in… 
2018
2018
Detection of Sotatercept (ACE-011) in human serum by SAR-PAGE and western single blotting.
A method for the detection of Sotatercept (ACE-011, ACVR2A-Fc) in human serum is presented. The method is a modification of a… 
2017
2017
Antibody-based strategies for the detection of Luspatercept (ACE-536) in human serum.
Luspatercept (ACE-536, ACVR2B-Fc), a fusion protein consisting of the extracellular domain of ActRIIB receptor and the Fc-part of… 
2016
2016
Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia
Introduction: Anemia is common in MPN-associated myelofibrosis (MF), and current therapies (e.g., erythropoiesis stimulating… 
Review
2016
Review
2016
Investigational therapies for renal disease-induced anemia
ABSTRACT Introduction: The main pillars for the treatment of chronic kidney disease (CKD) associated anemia are peptidic… 
Review
2015
Review
2015
The ESA scenario gets complex: from biosimilar epoetins to activin traps.
Recombinant human erythropoietin (rhEpo, epoetin) has proved beneficial in preventing transfusion-dependent anaemia in patients… 
2015
2015
Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Introduction Anemia and bone disease are hallmarks of multiple myeloma (MM). Sotatercept (ACE-011) is a novel, first-in-class… 
2015
2015
Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in Patients With End-Stage Kidney Disease on Hemodialysis
• In an ongoing study of sotatercept in HD subjects for the correction of anemia, subjects responding to an erythropoietin… 
2014
2014
An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic…
Introduction: Anemia, a hallmark of MDS, is challenging to treat, particularly after failure of erythropoiesis-stimulating agents… 
Review
2013
Review
2013
A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results
Background Beta (β)-thalassemia is characterized by ineffective erythropoiesis leading to anemia, bone marrow erythroid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)